Citations

Clear

1887 citation(s) found for "Thompson, RH".

Enterochromaffin cells as a cellular integration hub for cooperative microbial signaling to modulate gut serotonin and motility
Xiao, Yang , Till, Lisa , Gupta, Yash, Mercado‐Perez, Arnaldo , Bhagwate, Aditya V., Bellampalli, Shreya S. , Stark, Alejandro , Sekhon, Prabhjot K., Singh, Vaidhvi , Tienter, Dennis, Thompson, Michael A. , Kossick, Kimberlee , Krueger, Eugene W., Kalari, Krishna R., Hawkins, Kaitlyn R., Edwards, Brian S. , Alcaino, Constanza, Guo, Chun‐Jun , Druliner, Brooke R., Ördög, Tamás , Farrugia, Gianrico , Kashyap, Purna , Louwies, Tijs, Mars, Ruben A T, Mercado-Perez, Arnaldo, Bellampalli, Shreya S , Stark Quiroz, Alejandro , Liu, Rongfang , Thompson, Michael A , Kossick, Kimberlee , Lee, Jeong-Heon , van der Es, Daan , Willett, Julia L E , Wongkrasant, Preedajit , Prakash, Y S , Ordog, Tamas , Farrugia, Gianrico , Beyder, Arthur , Smith-Edwards, Kristen M , Kashyap, Purna C , Louwies, Tijs , Mars, Ruben A. , Gupta, Yash , Bhagwate, Aditya , Sekhon, Prabhjot Kaur , Heitman, Laura H. , Krueger, Eugene W. , Lee, Jeong‐Heon , Alcaino, Constanza , Willett, Julia L. E. , Wongkrasant, Preedajit , Prakash, Y. S. , Druliner, Brooke R. , Beyder, Arthur

Mayo Clinic

Proceedings of the National Academy of Sciences | August 24, 2026 | Volume: 123 | Issue: 35 | Pages: No page available

10.1073/pnas.2533336123 | PMID 42636369 Get It

The intestinal epithelium is exposed to diverse combinations of microbiota-derived compounds; however, the mechanisms by which the host integrates these signals remain poorly defined. Studying two highly abundant microbial metabolites, we identified the purine metabolite hypoxanthine as an effector metabolite that directly drives signaling and the short-chain fatty acid butyrate as a regulatory metabolite that conditions host responsiveness. Specifically, hypoxanthine activates the adenosine A1 receptor–TRPC4 axis in enterochromaffin (EC) cells, triggering calcium influx and serotonin release resulting in accelerated gastrointestinal transit locally and increased platelet activation systemically. In contrast, butyrate epigenetically upregulates specific G protein–coupled receptors and ion channels to enhance response to hypoxanthine and the neurotransmitters norepinephrine and dopamine. These findings define a cooperative signaling framework and highlight the role of EC cells as a distinct epithelial signaling hub that senses and integrates microbial metabolite signals to drive physiological responses. Our findings provide a mechanistic foundation for therapeutic strategies that leverage combinatorial microbial signaling.
CT Diagnosis of Abdominal Compartment Syndrome
Sandrasegaran, Kumaresan , Thompson, Cole P. , Lombardi, Alecio F., Jain, Ayana, Krishnan, Ishaan, Zulfiqar, Maria

Mayo Clinic

Journal of Gastrointestinal and Abdominal Radiology | August 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0046-1827199 Get It

Abstract Abdominal compartment syndrome (ACS) is defined as elevated intra-abdominal pressure resulting in dysfunction of at least one thoracoabdominal organ. Diagnosing ACS is particularly challenging in critically ill patients. This study aimed to identify specific CT imaging findings predictive of ACS by comparing cohorts with a clinical diagnosis of ACS and critically ill patients without this diagnosis. A retrospective case–control study identified patients with a clinical diagnosis of ACS. A matched control cohort consisted of critically ill patients without a diagnosis of ACS. Three radiologists, blinded to the patients' diagnosis and clinical course, reviewed CT scans for 19 different signs. Univariate analysis, logistic regression, and receiver operating characteristic (ROC) curve analysis were performed. Thirty-one patients with ACS and 36 without ACS were enrolled. On univariate analysis, abdominal anteroposterior-to-transverse dimension ratio (AR; p = 0.0002), peritoneal to abdominal height ratio (PAR) (p = 0.007), contour changes of solid organs (CCSO) (p = 0.005), and retroperitoneal collections (p = 0.02) were significant. On logistic regression analysis, only PAR was significant (p = 0.01). The presence of at least one of PAR >0.52 or AR >0.75 had sensitivity of 81% and specificity of 81% for predicting ACS. The presence of both of these signs had a specificity of 100% for ACS. Radiologists should consider ACS in critically ill patients when CT shows increased AR or PAR. CCSO and large retroperitoneal collections are secondary signs. Recognition of these imaging findings may aid in the timely and accurate diagnosis of ACS in clinical practice.
Geographic variation in certified headache subspecialty availability in the United States
Ong, Bradley , Thompson, Nicolas, Mueller, Heidi, Starling, Amaal J., Cheng, Nan , Thompson, Nicolas R. , Starling, Amaal J.

Mayo Clinic

Headache: The Journal of Head and Face Pain | August 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/head.70197 | PMID 42619617 Get It

Abstract Objectives/Background Our objectives were to characterize the geographic distribution and local availability of United Council for Neurologic Subspecialties‐certified headache specialists across US counties, hospital referral regions, and states, and to examine associations with socioeconomic deprivation, social vulnerability, and urbanicity. Headache disorders are highly prevalent and disabling, yet local availability of certified headache subspecialty care in the United States remains uneven. Although prior studies have described national and state‐level distributions of United Council for Neurologic Subspecialties‐certified headache specialists, important gaps remain in understanding county‐level availability and disparities in access. Prior state‐level summaries may mask within‐state differences in access to United Council for Neurologic Subspecialties‐certified headache specialists. Methods We conducted a cross‐sectional geospatial workforce analysis of United Council for Neurologic Subspecialties‐certified headache specialists in the United States as of January 7, 2026. Practice locations were mapped to counties, hospital referral regions, and states, and compared with general neurologist supply from the National Provider Identifier registry. Estimated population need was calculated by applying a national migraine prevalence to adult population denominators. We examined associations between specialist distribution and county‐level socioeconomic vulnerability, urbanicity, and region. Results Among 3144 US counties, 2870 (91.3%) had no United Council for Neurologic Subspecialties‐certified headache specialists, and 2085 (66.3%) had no neurologists. Headache specialists were entirely absent from counties without neurologists. Median county‐level headache specialist density was 0 per 100,000 adults, reflecting the absence of local subspecialty care in most US counties. Accounting for county adult population, neurologist density, urbanicity, and region, higher Area Deprivation Index and Social Vulnerability Index scores were associated with lower headache specialist rates. Each 10‐point increase in Area Deprivation Index was associated with lower expected headache specialist rate (adjusted incidence rate ratio = 0.87, 95% confidence interval = 0.82–0.93), and each 0.1‐unit increase in Social Vulnerability Index was also associated with lower expected rate (adjusted incidence rate ratio = 0.94, 95% confidence interval = 0.90–0.98). Headache specialist availability relative to estimated population need varied markedly across counties, with substantial estimated local differences between migraine burden and certified subspecialty supply that were not apparent in state‐level summaries. Conclusion United Council for Neurologic Subspecialties‐certified headache specialists are unevenly distributed across the United States, with limited local availability of certified headache subspecialty care in socioeconomically disadvantaged and nonmetropolitan counties. County‐level analyses identified substantial local gaps in certified headache subspecialty availability that were not apparent in state‐level summaries.
Perinatal and Early-Life Exposures and Risk of Non-Hodgkin Lymphoma
Cholack, George , Kleinstern, Geffen , Robinson, Dennis P. , Thompson, Carrie A. , Call, Timothy G. , Feldman, Andrew L. , Larson, Melissa C. , Mwangi, Raphael , Ansell, Stephen M. , Novak, Anne J. , Kay, Neil E. , Slager, Susan L. , Cerhan, James R. , Cholack, George A , Habermann, Thomas , Cozen, Wendy , Slager, Susan L , Cerhan, James R , Feldman, Andrew L , Kay, Neil E , Ansell, Stephen M , Novak, Anne J , Call, Timothy G , Larson, Melissa C , Habermann, Thomas M. , Cozen, Wendy

Mayo Clinic

Cancers | August 18, 2026 | Volume: 18 | Issue: 16 | Pages: 2666

10.3390/cancers18162666 | PMID 42649977 Get It

Background: Perinatal and early-life factors may influence non-Hodgkin lymphoma (NHL) risk, but study results have been mixed and exposure data for childhood ages are limited. Herein, we investigated associations of these exposures with risk of NHL and common subtypes. Methods: This case–control study included 2280 NHL cases and 2253 controls, enrolled from 2002 to 2014 at the Mayo Clinic Rochester. Self-reported perinatal and early-life exposures included maternal age at birth, birth order, birthweight, time breastfed, height and weight at ages 7, 12, and 18 years relative to peers, and age and weight when growth ceased. We used logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs), adjusting for design variables and potential confounders. Linear trend tests were performed for ordinal variables, and heterogeneity tests were performed to evaluate whether associations varied across four NHL subtypes. Results: After multivariable adjustment, greater birth weight (OR = 1.15 for quartile 4 vs. 1; p-trend = 0.04), weight at age 7 relative to peers (compared to average, OR = 1.05 for heavy and OR = 0.87 for thin; p-trend = 0.002), and weight when growth ceased (OR = 1.30 for quartile 4 vs. 1; p-trend < 0.001) were associated with increased NHL risk. An inverse association was observed for breastfeeding duration with NHL risk (OR = 0.77 for >6 months vs. never; 95% CI 0.61–0.97). Associations did not significantly vary by major NHL subtype (p-heterogeneity > 0.05). Other perinatal and early-life exposures were not associated with NHL risk. Conclusions: Greater body weight at birth and through childhood may be associated with increased NHL risk, potentially extending the life-course perspective on adiposity and lymphomagenesis, with implications for prevention.
Spatial Logic Reconciles Gene-signature Methods in Triple Negative Breast Cancer
Bastian, William C, Lee, Ji‐Hoon , Griffiths, Lyra Maria, Aiello, Meili, Buchwald, Zachary Scott, Thompson, E. Aubrey, Li, Zaibo , Li, Xiaoxian , Meisel, Jane Lowe , Shaker, Nada , Griffiths, Lyra M., Buchwald, Zachary S. , Liu, Yi , Thompson, E. Aubrey , Douglass, Eugene

Mayo Clinic

No container title available | August 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.13.744259 | PMID 42845422 Get It

Abstract Triple-Negative Breast Cancer (TNBC) presents a significant clinical challenge due to its heterogeneity and lack of targeted treatment options, with chemotherapy and immunotherapy combinations currently serving as the main therapeutic strategy. Efforts to address TNBC heterogeneity have largely focused on classifying intrinsic cancer subtypes based on differential tumor mRNA expression, a strategy that has proven effective in hormone receptor-positive breast cancers but has yet to yield a clinically useful predictor of survival or treatment response in TNBC. We hypothesize that both the intrinsic characteristics of TNBC and the surrounding immune microenvironment influence treatment outcomes and that immune cell infiltration affects TNBC subtype classification and response variability. To explore this hypothesis, we compared the predictive and prognostic capabilities of cancer subtype-based (TNBC-type) gene signatures and immune cell deconvolution methods (CIBERSORT) within the same TNBC datasets. We found that immune cell abundance outperformed TNBC subtype-signatures and multicellular immune cell aggregates showed the highest performance of all. More specifically, aggregate immune cells associated with tertiary lymphoid structures and tumor associated macrophages/monocytes demonstrated statistically significant predictive value. These findings were confirmed in an independent cohort of 67 TNBC patients treated with neoadjuvant chemotherapy. Further, single-cell RNA sequencing analysis revealed that the predictive power of cancer-subtype could be partially explained by immune- and stromal features. Examination of single-cell resolution spatial transcriptomic data confirmed presence of TLS-like, TAM- and cancer-stromal niches within TNBC biopsy samples that were associated with treatment response. Overall, our results highlight that immune cell aggregates, which capture the spatial organization of the TME, outperform cell-type specific gene signatures in predicting TNBC outcomes. Our novel approach provides a robust framework for interpreting spatial relationships in bulk RNA-seq data, offering a pathway for reconciling past data with current advancements in spatial profiling technologies. This work paves the way for future studies to leverage the multi-cellular complexity of TNBC, enhancing diagnostic precision and facilitating the development of therapies that strategically modulate the tumor microenvironment for improved anti-cancer responses.
A phosphorylation switch governs KIF11’s mechanical output during mitosis
Šemić, Amila , Reddy, Babu J.N., Muretta, Joseph M. , Vandal, Sarah E. , Thompson, Alex F. , Fonseca, Cindy L., Rosenfeld, Steven S. , Gross, Steven P. , Stumpff, Jason

Mayo Clinic

Proceedings of the National Academy of Sciences | August 11, 2026 | Volume: 123 | Issue: 33 | Pages: No page available

10.1073/pnas.2602415123 | PMID 42579498 Get It

The kinesin-5 motor protein KIF11 is crucial for mitotic spindle assembly, driving the separation of spindle poles through microtubule sliding. Src-family kinases phosphorylate KIF11 at multiple tyrosine residues within its motor domain, but the mechanistic consequences of these modifications remain unclear. Here, we dissect the role of phosphorylation at Y211 using phospho-mimetic (Y211E) and nonphosphorylatable mutants (Y211F) in biochemical, biophysical, and cellular assays. Optical trapping and Förster resonance energy transfer analyses reveal that Y211 phosphorylation slows neck-linker docking, reducing motor velocity and force generation under load. In human cells, Y211E expression impairs bipolar spindle formation and decreases spindle pole separation velocity, while Y211F shortens steady-state spindle length. Fluorescence recovery after photobleaching analyses show that Y211E accelerates motor turnover on spindle microtubules, consistent with the mutant motor’s heightened load sensitivity. Together, these findings support a model in which Src-mediated phosphorylation at Y211 acts as a rheostat to tune KIF11 mechanochemistry and spindle assembly dynamics, linking cancer-relevant kinase signaling to mitotic force generation.
Polymeric nanoparticle-mediated siRNA delivery into primary human bronchial airway cells
Thompson, Michael A., Hamrick, Samantha K. , Borkar, Niyati A. , Ravi, Preetham , Çiçek, Yağız Anıl , Lehot, Victor , Goswami, Ritabrita , Nagaraj, Harini , Nasim, Nourina , Rotello, Vincent M , Pabelick, Christina M , Prakash, Y S , Borkar, Niyati , Rotello, Vincent M. , Pabelick, Christina M. , Prakash, Y. S.

Mayo Clinic

American Journal of Physiology-Cell Physiology | August 10, 2026 | Volume: 331 | Issue: 3 | Pages: C783-C796

10.1152/ajpcell.00127.2026 | PMID 42572107 Get It

siRNA delivery to target cellular processes is an appealing area in lung diseases such as asthma. To realize this potential requires efficient, targeted cytosolic delivery without cellular toxicity or siRNA degradation. We demonstrate the efficacy of PONI-Guan nanoparticles in accessing airway epithelial and smooth muscle cells with specific siRNA targeting of mRNAs of interest while maintaining barrier integrity and avoiding cellular toxicity.
Robotic vs Laparoscopic Cholecystectomy: Preoperative and Intraoperative Severity-Adjusted Outcomes with Strasberg-Classified Bile Duct Injury
Kandil, Omneya, Rehman, Nisha, Saleeb, Andrew, Thompson, Emily, Krosch, Tara, Veenstra, Benjamin, Nelson, Megan, Abutaka, Ahmad, Fong, Zhi Ven, Jorge, Irving, Joshi, Devendra, Kandil, Omneya , Saleeb, Andrew G. , Krosch, Tara C., Beckermann, Jason , Nelson, Megan H., Fong, Zhi Ven , Jorge, Irving

Mayo Clinic

Journal of the American College of Surgeons | August 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/xcs.0000000000002118 | PMID 42566036 Get It

Background: Whether robot-assisted cholecystectomy reduces bile duct injury compared with laparoscopic cholecystectomy remains uncertain because prior studies have inadequately accounted for disease severity and have rarely classified injury severity using standardized criteria. This study compared perioperative outcomes after robot-assisted and laparoscopic cholecystectomy across a large healthcare system while adjusting for operative complexity. Study Design: Adults undergoing robot-assisted or laparoscopic cholecystectomy within the Mayo Clinic Enterprise (2014–2025) were retrospectively evaluated. Propensity score weighting adjusted for demographics, surgeon case volume, learning curve, and disease severity using the Tokyo Guidelines and Parkland grading system in patients with acute cholecystitis. The primary outcome was bile duct injury; secondary outcomes included general and procedure-specific complications. Results: Among 23,513 patients (19,998 laparoscopic; 3,515 robotic), robot-assisted cholecystectomy was used more frequently for Parkland grade ≥3 disease. Overall, 227 bile duct injuries occurred (204 laparoscopic; 23 robotic), corresponding to absolute risks of 1.02% and 0.65%, respectively (absolute risk difference −0.37%, 95% CI −0.72% to −0.02%; number needed to treat, 273). Robot-assisted cholecystectomy was associated with lower odds of conversion to open surgery, 30-day readmission, and mortality, shorter hospital stay (β −0.56, 95% CI −0.66 to −0.45; P<0.001), and a 5-minute longer median operative time. In acute cholecystitis, robot-assisted cholecystectomy was associated with lower adjusted odds of bile duct injury (aOR 0.29, 95% CI 0.07–0.78; P=0.011). Conclusions: After adjustment for disease severity and surgeon-related factors, robot-assisted cholecystectomy was associated with lower odds of bile duct injury in acute cholecystitis and improved perioperative outcomes, including shorter hospitalization and lower conversion rates, despite greater use in more complex cases.
TLSB-18 CLINICAL UTILITY OF CEREBROSPINAL FLUID CIRCULATING TUMOR DNA ASSAY IN PATIENTS WITH SUSPECTED LEPTOMENINGEAL DISEASE: A REAL-WORLD DESCRIPTIVE ANALYSIS
Mrugala, Maciej, Bendok, Bernard, Alyx, Porter, Texidor, Rhonda, Thompson, Tracy, Vora, Sujay, Ensign, Shannon Fortin, Vora, Sujay A., Ensign, Shannon P. Fortin

Mayo Clinic

Neuro-Oncology Advances | August 7, 2026 | Volume: 8 | Issue: Supplement_6 | Pages: No page available

10.1093/noajnl/vdag161.136 Get It

Abstract Background Leptomeningeal disease (LMD) remains a challenging complication of both solid tumors and hematologic malignancies, with diagnosis traditionally relying on cerebrospinal fluid (CSF) cytology, which has limited sensitivity. Circulating tumor DNA (ctDNA) analysis in CSF has emerged as a promising diagnostic and molecular profiling tool that may improve detection and guide treatment decisions. We will report real-world clinical experience using a CSF ctDNA assay (Menarini Silicon Biosystems) in routine neuro-oncology practice. Methods Retrospective analysis of over 100 CSF specimens obtained from patients with suspected or confirmed LMD will be conducted. Clinical data to be collected: patient demographics, tumor histology, indication for testing, and prior treatments. ctDNA assay results will be compared with conventional CSF cytology. Molecular alterations identified through ctDNA testing will be recorded, along with subsequent treatment decisions, including use of targeted therapies, systemic therapy modifications, radiation therapy, or intrathecal approaches. Preliminary clinical outcomes, including radiographic response, progression patterns, and survival trends, will be explored. Descriptive statistical methods will be used to summarize the findings. Results We anticipate that among analyzed specimens, ctDNA testing will provide clinically meaningful diagnostic yield across multiple tumor histologies. Concordance and discordance patterns between ctDNA results and conventional cytology will be evaluated, including cases in which ctDNA identified molecular alterations despite negative cytology. Actionable genomic findings in a subset of patients will be analyzed and presented. Early outcome observations that ctDNA-informed management may facilitate more personalized care will be reported. Conclusions CSF ctDNA analysis represents a feasible and informative adjunct to conventional cytology in the evaluation of patients with suspected LMD in real-world clinical practice. Beyond diagnostic support, molecular profiling from ctDNA may influence treatment selection and enable precision oncology approaches in this high-risk population. Prospective studies are warranted to define sensitivity, specificity, and the impact of ctDNA-guided interventions on clinical outcomes.
WSB1-Mediated PSMA Ubiquitination Promotes Enzalutamide-Induced Neuroendocrine-like Transition in Patient-Derived Prostate Cancer Spheroids
Jung, Dawa, Kendi, A. Tuba , Woodrum, David A. , In, Myung‐Ho , Bilgin, Gokce Belge , Johnson, Derek R. , Kim, Eun-Joo, Chung, Jin Ook , Park, Seon-Young , Curran, Geoffry L., Lowe, Val J. , Lee, Seung Baek , Kendi, A Tuba , Adamo, Daniel A. , In, Myung-Ho , Belge Bilgin, Gokce , Johnson, Derek R , Horn, Ian M, Lowe, Val J , Lee, Seung Baek , Thompson, Scott M. , Horn, Ian M. , Curran, Geoffry L.

Mayo Clinic

International Journal of Molecular Sciences | August 3, 2026 | Volume: 27 | Issue: 15 | Pages: 6899

10.3390/ijms27156899 | PMID 42589556 Get It

Long-established prostate cancer cell lines provide limited insight into how contemporary early prostate cancer evolves into drug-resistant and neuroendocrine-like refractory disease. Patient-derived three-dimensional (3D) ex vivo models may better preserve this transition. Here, we found that 8 of 10 magnetic resonance imaging-guided biopsy specimens from patients with early-stage prostate cancer generated sustained 3D tumor spheroid cultures. After 12 weeks of enzalutamide selection, only one patient-derived culture acquired a resistant phenotype with treatment-emergent neuroendocrine prostate cancer (t-NEPC)-like features, including increased chromogranin A (CgA) and synaptophysin (SYP); reduced androgen receptor (AR), prostate-specific antigen (PSA), and prostate-specific membrane antigen (PSMA); and conversion from compact spheroids into irregular resistant aggregates. During this transition, WD repeat and SOCS box-containing protein 1 (WSB1) increased, whereas PSMA progressively decreased. WSB1 silencing restored PSMA, AR, and PSA expression and reduced neuroendocrine-associated features. A similar WSB1 dependency was observed in enzalutamide-resistant LNCaP cells, the castration-resistant prostate cancer model 22Rv1, and the neuroendocrine/small-cell prostate cancer model NCI-H660. Mechanistically, WSB1 functioned as a SOCS box-dependent E3 ubiquitin ligase adaptor that promoted PSMA ubiquitination and degradation. SOCS box deletion or T380A mutation impaired this process, while Aurora kinase A (AURKA) inhibition reduced WSB1-dependent PSMA ubiquitination. WSB1 depletion, AURKA inhibition with alisertib, and combined AURKA inhibition with EZH2 suppression reduced resistant aggregate growth and increased apoptosis-associated markers in patient-derived enzalutamide-resistant neuroendocrine-like spheroids and related models. These findings nominate the AURKA–WSB1–PSMA axis as a therapeutic vulnerability in refractory prostate cancer.